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ABSTRACT. Purpose. Continuity of care, 
equitable access, and quality and safety are major 
foci in health services management. The introduction 
of limited prescribing rights to pharmacists has the 
potential to reduce fragmentation within the health 
system, optimise medication management, improve 
continuity of patient care and improve patient access 
to medication. Results. Eight models for 
pharmacists’ prescribing have been implemented 
internationally, varying in their dependency on 
protocols, formularies and collaboration with 
physicians.  These have also been described using 
terms such as Supplementary Prescribing and Patient 
Group Directions. Conclusion. Issues relating to 
practical implementation of pharmacists’ prescribing 
include negotiation of national health policy, 
pharmacists’ training and accreditation, liability, 
reimbursement and documentation.  
 
INTRODUCTION  
 
There has been significant change in the supply of 
medicines over the last few decades. Technology has 
made recording of prescriptions less time-consuming 
and the storage and access of patient histories more 
reliable. The use of technicians to undertake routine 
tasks has facilitated the introduction of medication 
review services utilising pharmacists’ drug 
knowledge. Effective use of professional expertise 
and health  resources  should  eliminate   inefficiency 
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and duplication of effort (1-3) in healthcare delivery. 
Prescribing requires knowledge of adverse effects, 
doses, optimal routes, drug-drug and drug-food 
interactions, pharmacokinetics, pharmacodynamics 
and monitoring of effects. Application of this 
knowledge requires significant expertise. (4) 
Most medication-related interventions by 
pharmacists occur retrospectively; their earlier 
involvement in the prescribing process may help 
optimise the use of medicines. (5-7) Pharmacists’ 
interventions in medication management, including 
monitoring of therapy, are accepted in the hospital 
setting. (8) Extending this process by adding the 
right to prescribe  (select) initial therapy and to 
adjust ongoing therapy is a relatively small step, and 
arguably, simply formalises a process that is already 
beginning. 
There has been considerable discussion in 
the literature about the pros and cons of new 
professional practice models for pharmacists, 
including prescribing. It has been argued that 
pharmacists are developing expertise in evidence-
based practice and patient-centred care, suiting them 
to taking responsibility for prescribing and 
monitoring therapy (2) with potential benefits for 
medical practitioners.  
Over time, pharmacists have been 
prescribing an increasing range of medications. In 
many countries, the existence of ‘pharmacist only’ 
medicines recognises the expertise and competence 
of pharmacists to prescribe. (2) Further, in a number 
of countries, pharmacists are already able to legally 
prescribe a range of medicines previously only 
prescribed by medical practitioners. (9-11)  
With this general acceptance of pharmacist 
prescribing in the international pharmacy literature, it 
is timely to investigate the implementation of 
pharmacist prescribing models internationally. These 
models are discussed below, categorised according to 
their degree of independence.  
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Independent prescribing  
 
Independent prescribing occurs where the 
prescribing practitioner is solely responsible for 
patient assessment, diagnosis and clinical 
management (2) and requires legally defined levels 
of knowledge and skill that are usually monitored 
through a licensing process (2,12). No examples of 
unrestricted independent pharmacist prescribing were 
identified in the literature.  
 
Dependent prescribing: prescribing by protocol  
 
‘Dependent’ prescribing incorporates more 
restriction on prescribing activities, via protocols or 
formularies. Prescribing by protocol is the most 
common form of dependent prescribing, (13) and is 
defined as “delegation of authority from an 
independent prescribing professional, usually a 
physician”, involving a formal agreement  (protocol). 
(12) The protocol is a written guideline, (12) an 
explicit, detailed document that describes the 
activities pharmacists may perform in their 
prescriptive authority (12,13).  
The protocol lists: 
• Types of diseases, drugs/drug categories (12,13) 
and prescriptive decisions covered by the 
agreement (7) 
• The procedure, decision criteria or plan that the 
pharmacist must follow when prescribing (12,13) 
• The physician and pharmacists party to the 
agreement (7) 
• The time limit for the agreement (7) 
• The responsibilities of each of the parties 
involved (12) 
• The documentation required (7,12) and feedback 
mechanisms to the authorising prescriber (12) 
• Policies for review and revision of the protocols. 
(12)  
The level of authority should be determined by 
physicians’ assessments of the pharmacists’ 
competence, pharmacists’ assessment of their own 
competence, and pharmacists’ comfort with these 
roles (11). Both parties should be willing to share 
responsibility for patient outcomes (12). 
Many drug groups have been deemed 
suitable for pharmacists’ prescribing by protocol, 
including anticoagulants (12,14,15), analgesics  
(12,14,15), antiemetics (12,15) and antihypertensives 
(11,12,14). 
Nurse prescribing under protocols, known as 
‘standing orders’, is common in hospitals (16). In 
New Zealand, any registered health professional can 
enter into ‘dependent’ prescribing arrangements with 
authorised prescribers under ‘standing orders’ or 
protocols (17).  
In the United States of America  (USA), 
protocol-based prescribing had been successfully 
legislated in at least 25 states by 2001 (1,12). The 
prescriptive authority requires prior state Board 
notification of the written protocol (7,11). In the 
USA, Indian Health Service  (IHS) pharmacists can 
prescribe for patients with disease states including 
ear infections, urinary tract infections, sexually 
transmitted diseases, congestive heart failure, 
hypertension, seizures, bacterial and fungal 
infections, arthritis and conjunctivitis (11). In 1979, 
the IHS reported that physicians had judged the 
quality of pharmacists’ care as not significantly 
different to their own. The IHS model was also 
beneficial for patient satisfaction and pharmacist-
physician relationships, reduction in physician 
referrals, and improvement in clinic efficiency  (11).  
Credentialing is another issue addressed in 
this model. Local pharmacies were permitted to 
determine the scope of practice and establish the 
credentials needed for prescribing. Prescribing 
pharmacists generally required a PharmD or MS 
degree, or equivalent qualification, specialty board 
certification or two years of clinical experience (11). 
The facility’s medical committee or chief executive 
officer then approved the scope of practice based 
upon competence, not educational attainment.  
Policy changes included the application of 
formal written protocols and standing orders for 
prescribing, requiring legislative change. Quality 
assurance was provided by retrospective chart 
reviews by physicians. 
It has been proposed that prescribing by 
protocol can lead to containment of drug costs (14), 
reduction of medical practitioner visits, (18) 
integration with medication reviews, (18) and 
improving access to medicines, for example the 
emergency contraceptive pill. (14) In contrast, it may 
remove some interaction with the physician 
undertaking diagnosis (18), create extra workload for 
the prescriber (18), complicate reimbursement for 
prescribing, (14,18) require pharmacists to 
compromise other professional duties (17) and 
arguably lead to more room for error by involving 
more staff.  
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Implementation issues include coordination 
of information and access (17), accreditation, 
education, accountability and competency 
assessment, (11,17) determination of scope of 
practice (17) and gaining of prescriptive authority 
(15).  
 
Dependent prescribing models: Patient Group 
Directions  
 
A Patient Group Direction  (PGD) is a written 
direction signed by a doctor or dentist, and by a 
pharmacist, relating only to supply and 
administration of a prescription medicine (1,19). The 
recipients are any patients (1,19,20), who may not be 
individually identified before presentation for 
treatment. (21) The PGD applies if a number of 
specified requirements are met (20), subject to any 
specific exclusions listed (19).  
The PGD is a United Kingdom  (UK) model 
that can be authorised by designated NHS bodies in 
the UK. (1,19) Trials have been reported in 
Manchester, two health authorities in London, South 
Derbyshire, Walsall and Bridgend (19).  
The PGD must specifically name the 
Prescription Only Medicine or class of medicines, 
dosage form(s), applicable dosage or maximum 
dosage, route of administration, frequency of dosing, 
minimum/maximum period for administration, 
relevant warnings, restrictions on quantity, 
circumstances in which the medicine can and cannot 
be supplied, when further advice should be sought, 
follow-up action, records to be kept, and the valid 
period for the PGD (19).  
Specific drugs listed in the literature for 
prescribing by PGD are emergency hormonal 
contraception, (19) combined oral contraceptives 
(22) and antihistamines  (30-day courses)  (23).  
NHS-accredited pharmacists prescribing by 
PGD require dedicated training. Privacy during 
consultations remains an issue (22). Pharmacists 
should be able to manage this service concurrently 
with their provision of ‘pharmacist only’ medicines 
(19).  
 
Dependent prescribing models: prescribing by 
formulary  
 
In formulary-based prescribing, local formularies are 
agreed between participating medical practices and 
community pharmacies. (1) The formulary is a 
limited list of medicines (12,13), including treatable 
symptoms, length of treatment, criteria for referrals 
and limitations for prescribing (23). Many of the 
formulary medicines are those already available 
without prescription in a similar formulation or lower 
potency (24). The model is less explicit than protocol 
prescribing (12,13).  
In the UK around 21,700 nurses are reported 
to be able to prescribe from the Nurse Prescribers’ 
Formulary, and 400 are qualified to prescribe from 
the Nurse Prescribers’ Extended Formulary. As at 
October 2002, only 11,100 were actively prescribing 
(25).  
A Scottish study of pharmacists’ prescribing 
by formulary included 11 therapeutic areas (23). 
There was no evidence of abuse of the system in the 
Scottish trial, and the scheme was well received by 
patients (23).  
The model requires considerable record-
keeping, and has been perceived to add liability to 
pharmacists (24). Policy issues also include 
prevention of over-prescribing to patients consulting 
more than one pharmacist (23). The optimal physical 
environment in the pharmacy should be determined 
such as an extra pharmacist and private consultation 
area (23). If this scheme were widely adopted, a 
national pharmacy formulary would be 
recommended (23).  
 
Dependent prescribing models: prescribing by 
patient referral  
 
Patients (1), practice staff (1,12) or another 
community pharmacist (1) may refer patients to a 
pharmacist for a prescription. Typically, patients 
would be individually referred to a pharmacist by a 
physician for “management of specific drug therapy 
or to achieve a specific therapeutic outcome”  
(12,13). The most common example of this model is 
the ambulatory care setting within a health care 
facility (12,13).  
A trial of patient referral to pharmacists  
(with formulary-guided prescribing) in Merseyside, 
UK, involved 12 minor ailments (26). A single 
medical practice referred 38% of all presentations to 
one of eight pharmacies. Patients were less likely to 
accept referral if they perceived a need for a 
physician’s examination, if previous self-treatment 
had been unsuccessful, if the patient was a child, if 
the patient had a concomitant condition or influential 
medical history, or self-perceived a need for an 
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antibiotic. In this study, physicians’ workload 
dealing with minor ailments decreased from 8.9% to 
6.6% due to the referral system, and patients reported 
saving time and had improved accessibility to 
providers and treatments. The program costs were 
“not substantial”, and overall prescribing costs did 
not increase. The referral model involved 
identification of eligible ailments at the medical 
practice and offering pharmacists’ consultation. A 
consultation form was completed by reception staff 
and faxed to the chosen pharmacy, where the 
pharmacist recommended a medicine from the 
formulary or referral back to a medical practitioner. 
Pharmacists were paid £1.50 for their professional 
input, while medicines were supplied under NHS 
subsidy.  
 
Dependent prescribing models: repeat 
prescribing  
 
Repeat prescribing involves pharmacists providing 
medication-refill services in clinics associated with 
medical centres, for patients who have exhausted 
their prescribed drugs before their next physician 
appointment. The pharmacist assesses the patient and 
therapy and either: 
• Consults the attending physician if there are 
problems with compliance, disease control 
and/or side effects (11,27) 
• Writes refill prescriptions for dispensing at 
another pharmacy (14) or 
• Refills the medication with a sufficient quantity 
to last until the next available appointment. 
(11,27)  
Repeat prescribing has been discussed in the UK 
(28), and is allowed in some 28 states in the USA 
(14), although there is a paucity of literature on 
repeat prescribing trials. In the Australian system, the 
Pharmaceutical Benefits Scheme has in place a 
procedure for repeat prescriptions written by medical 
practitioners.  
 
Dependent prescribing models: supplementary 
prescribing  
 
Supplementary prescribing is a voluntary partnership 
between the independent prescriber and a 
supplementary prescriber, to implement an agreed 
patient-specific clinical management plan with the 
patient’s agreement (1,21,29). No clinical situations 
are listed in the definition, to avoid excluding others 
(1,21). Supplementary prescribing is not restricted to 
one-to-one prescriber partnerships, as patient care is 
largely delivered by teams (1).  
The independent prescribers are doctors or 
dentists (29,30). Supplementary prescribers are 
registered pharmacists or nurses (1,21,29,30). The 
independent prescriber undertakes the initial 
assessment (21,29) and the supplementary prescriber 
can then write prescriptions at public expense (1,29), 
working to a care management strategy that has been 
agreed by the physician (31).  
The supplementary prescriber’s roles include 
contributing to clinical management plan monitoring 
(1), changing the medicine and referring to the 
independent prescriber where appropriate (1), and 
recording clinically relevant facts (1,29).  
Central to the prescribing arrangement is the 
patient-specific clinical management plan that is 
evidence-based, consistent with recognised clinical 
guidelines, and agreed by prescribers and the patient 
or carer (1). Patients are involved in decision-making 
(29) and provide consent for the transfer of their 
information between prescribers (1). Prescribing and 
dispensing should be separate for patient safety and 
governance (1), if not, clear accountability 
arrangements should be in place (29).  
There is no restriction on the medical 
conditions to which this model applies (1,21), but 
supplementary prescribing is unlikely to be used for 
acute conditions (29). All medicines, excluding 
controlled drugs (21,29) and unlicensed medicines 
(21) may be prescribed.  
In the UK, supplementary prescribing was 
introduced in the Health and Social Care Act 2001. 
The Department of Health published an 
implementation guide in March, 2003. The 
implementation of this UK model has been thorough, 
addressing standards of practice to ensure public 
safety and probity (1) and distinguish between 
professional and commercial responsibilities (31). 
The majority of pharmacists trained to date are from 
hospitals, with the first registered in February 2004 
(21).  
Although evaluation is ongoing, 
supplementary prescribing is expected to 
demonstrate multiple benefits for health care delivery 
and organization (1), patient convenience (1,32), 
access (1,21,33), patient safety (21), concordance 
with clinical management plans (1), efficiency in 
general practice and hospitals (1), waste reduction 
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(1), doctors’ workload (21,32,33) and professional 
satisfaction for pharmacists (1).  
 
Collaborative prescribing models  
 
Collaborative prescribing requires a cooperative 
practice relationship between a pharmacist and a 
physician or practice group, with legal authority to 
prescribe medications (12). Explicit collaborative 
agreements are negotiated within each facility (12), 
outlining who is delegating and receiving authority, 
and demonstration of competence. The group of 
patients may be defined by the pharmacist’s 
expertise. In the USA, agreements must be filed with 
a State Pharmacy or Medical Board (2).  
The physician diagnoses and makes initial 
treatment decisions for the patient, and the 
pharmacist selects, initiates, monitors, modifies and 
continues or discontinues pharmacotherapy as 
appropriate to achieve the agreed patient outcomes. 
The physician and pharmacist share the risk and 
responsibility for the patient outcomes (13).  
Informally, clinical pharmacists in public 
and private hospitals have practised collaborative 
prescribing to some extent throughout the past 25 
years (8,20,34-37). Examples of collaborative 
prescribing by hospital pharmacists in Canada and 
the USA include aminoglycoside and 
pharmacokinetic dosing services, anticoagulant 
therapy adjustment and chemotherapy antiemetic 
management (12). By 2001, 27 American States had 
some form of legislation that allowed collaborative 
practice between pharmacists and physicians (38). In 
Minnesota, pharmacists may provide medicines for 
first dosages and in emergencies (39). Collaborative 
models are being considered in Canada for 
pharmacists’ prescribing (13,40), including initial 
drug selection or adjustments (12).  
A study has been undertaken to demonstrate 
the appropriateness of prescribing and monitoring by 
hospital pharmacists (20). Evidence also supports 
that provision of cognitive services by community 
pharmacists improves patient health outcomes and 
possibly reduces health care costs (41).  
An Australian hospital study found that a 
significant proportion of doctors would welcome 
pharmacists making written comments in the medical 
record notes (42,43). UK surveys, however, indicate 
that pharmacists, doctors and nurses have mixed 
feelings about the introduction of expanded roles for 
pharmacists (20,44,45).  
Implementation issues  
 
The eight models identified from the USA, UK, 
Canada and New Zealand have been mapped to 
demonstrate their variation in pharmacists’ authority 
and restrictions regarding product formularies 
(Figure 1).  
Despite the numerous commentaries in 
support of pharmacists’ prescribing, there is a lack of 
evidence about the impact of such models on 
practice and outcomes. There is potential for such 
models to be implemented in a rapidly changing 
health care system as the fundamental principles of 
patient-centered and integrated care in a financially 
and clinically responsible manner apply. There are 
many issues that must be addressed before such 
models can be implemented; these are discussed 
below.  
 
1. Professional issues  
 
Responsibility must be taken for the whole process 
of diagnosis, prescribing and follow-up, including an 
awareness of boundaries or limitations to expertise 
(46). Not all pharmacists may want to undertake this 
responsibility.  
There is a need for appropriate baseline and 
continuing professional education (12,46). It is 
probable that all registered pharmacists have the 
expertise required to undertake dependent 
prescribing without further intensive education, other 
than training in the prescribing process itself (2,3). It 
is important, however, that all pharmacists 
undertaking independent prescribing roles 
demonstrate competence, and that a register be kept 
of suitably qualified pharmacists (3). Collaborative 
prescribing may only require the assessment of 
competence at an institutional level (12). A 
contrasting viewpoint is the need for a uniform 
standard of competence for prescribing pharmacists, 
irrespective of the prescribing model utilised (9,47).  
The separation of dispensing and prescribing is 
seen as an important component of the ‘checks and 
balances’ ensuring that the most appropriate 
treatment is chosen for the patient. Pharmacists 
currently prescribe and dispense for minor 
conditions; however, extending this responsibility to 
prescription medicines may introduce new quality 
assurance issues.  
Periodic review of pharmacists’ prescribing 
practices may be required as a mechanism for 
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maintaining standards and ensuring optimal patient 
outcomes (3,11). Audits may focus on such activities 
as adherence to prescribing protocols, adverse events 
or outcomes assessment (48).  
Maintenance of, and access to, patient records 
are required when a pharmacist prescribes 
medication. The system should be comprehensive, 
effective and time efficient (48,49), and may require 
transfer of information back to the medical 
practitioner.  
 Securing remuneration for professional 
responsibility is another essential step in the adoption 
of prescribing rights. Pharmacists who have 
undertaken additional education and are prepared for 
the increased responsibility associated with 
prescribing should be appropriately compensated 
financially for this task (6,12). There are few models 
of remuneration available, and their international 
applicability is questionable. 
 
2. Changes to medication prescribing  
 
International developments show that enhanced 
clinical roles for pharmacists are valuable, and that 
pharmacists have the expertise to contribute to 
patient care. For widespread acceptance, services 
provided by pharmacists must be promoted to the 
public, health care system administrators and 
government (50). Pharmacist prescribers must also 
recognise the rights of consumers to choose the 
practitioner of their choice and to reject 
recommendations that are made (48).  
There may be resistance to change from 
within the pharmacy profession, and other 
professions may feel that prescribing pharmacists 
intrude on their area of professional responsibility 
(46). The careful development of collegial working 
relationships is essential in the acceptance of new 
prescribers.  
 With successful implementation of 
alternative prescribing models, costs for patients may 
decrease (46), as knowledge of the cost associated 
with therapeutic alternatives may inform treatment 
decisions. Costs for pharmacists may increase if the 
physical layout of the pharmacy requires 
modification to facilitate private counselling (3).  
 
 
 
Figure 1: Models of pharmacist prescribing 
 
 
 
No protocol
Protocol
Limited
formulary
Broad
formulary
Supplementary Prescribing
Protocol Prescribing
Collaborative Prescribing
Patient Group Direction
Repeat Prescribing
Referral to Pharmacists
Formulary Prescribing
Independent Prescribing
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3. Workload and workforce issues  
 
There are workforce-related issues related to 
pharmacists gaining prescribing rights. It may be 
possible that pharmacists who prescribe medicines 
spend less time seeking approval for changes to 
existing prescriptions or obtaining ‘owed’ 
prescriptions, therefore improving workload. 
Adopting and maintaining new services may present 
a challenge for the pharmacy profession in some 
countries where a shortfall in pharmacists has been 
predicted (50,51).  
 
4. Legal issues  
 
For successful implementation of pharmacist 
prescribing models, a statutory framework needs to 
be in place, and a separate register of those 
pharmacists who have been judged competent to 
practise as ‘prescribing pharmacists’ is 
recommended (52). Legal requirements may depend 
on the actual model implemented, considering the 
degree of responsibility required of the pharmacist.  
 
CONCLUSION  
 
There are many papers that voice opinion and 
rhetoric about pharmacists’ prescribing of 
Prescription Medicines. From the literature, we 
identified eight relevant models implemented 
internationally. The impact of these models on health 
outcomes and health care systems have not been well 
studied.  
If pharmacists are to be granted the right to 
prescribe, they must also accept the inherent 
responsibilities. Establishing a rigorous clinical 
governance framework will be critical to establishing 
prescribing models in any setting. There are 
numerous professional, technological, educational 
and legal issues that must be resolved before 
pharmacists can prescribe. The introduction of 
collaborative or supplementary prescribing models 
may be an appropriate first step.  
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